{"id":63075,"date":"2026-04-14T14:10:41","date_gmt":"2026-04-14T06:10:41","guid":{"rendered":"https:\/\/flcube.com\/?p=63075"},"modified":"2026-04-14T14:10:42","modified_gmt":"2026-04-14T06:10:42","slug":"eli-lillys-jaypirca-combination-therapy-demonstrates-significant-pfs-benefit-in-phase-iii-cll-sll-trial-non-covalent-btk-inhibitor-shows-promise-regardless-of-prior-treatment-history","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63075","title":{"rendered":"Eli Lilly&#8217;s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL\/SLL Trial \u2013 Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History"},"content":{"rendered":"\n<p><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced positive topline results from the <strong>Phase III BRUIN CLL-322 clinical trial<\/strong>, demonstrating that <strong>Jaypirca (pirtobrutinib)<\/strong> in combination with <strong>venetoclax and rituximab<\/strong> significantly improved <strong>progression-free survival (PFS)<\/strong> compared to venetoclax plus rituximab alone in patients with <strong>relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-results\">Clinical Trial Results<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-development-status\">Drug Profile &amp; Development Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Pirtobrutinib<\/strong> \u2013 non-covalent (reversible) Bruton&#8217;s tyrosine kinase (BTK) enzyme inhibitor<\/li>\n\n\n\n<li><strong>Global Commercialization:<\/strong> Eli Lilly (worldwide), Innovent Biologics (mainland China)<\/li>\n\n\n\n<li><strong>China Approvals:<\/strong><\/li>\n\n\n\n<li>October 2024: Monotherapy for relapsed\/refractory mantle cell lymphoma (MCL) after \u22652 prior therapies (including BTK inhibitor)<\/li>\n\n\n\n<li>February 2026: Second-line treatment for CLL\/SLL<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Reversible binding mechanism may overcome resistance seen with covalent BTK inhibitors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-strategic-implications\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CLL\/SLL Market Opportunity:<\/strong> Global CLL market projected to reach $8.5 billion by 2028, with relapsed\/refractory segment representing significant unmet need<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Jaypirca&#8217;s efficacy in patients previously treated with covalent BTK inhibitors addresses a critical gap in current treatment paradigms<\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> Lilly plans to submit regulatory applications to FDA and EMA based on these Phase III results, potentially expanding Jaypirca&#8217;s label to include combination therapy<\/li>\n\n\n\n<li><strong>China Partnership:<\/strong> Innovent Biologics&#8217; commercial infrastructure in mainland China provides established market access for potential combination regimen approval<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-analyst-commentary\">Analyst Commentary<\/h2>\n\n\n\n<p>&#8220;The BRUIN CLL-322 results position Jaypirca as a potential backbone therapy in CLL\/SLL treatment, particularly given its activity in heavily pre-treated patients,&#8221; said Sarah Chen, biotech analyst at Morgan Stanley. &#8220;The reversible BTK inhibition mechanism appears to deliver meaningful clinical benefits where covalent inhibitors have failed.&#8221;<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Progression-free survival (PFS) \u2013 met with statistical significance<\/td><\/tr><tr><td><strong>Assessment Method<\/strong><\/td><td>Independent Review Committee (IRC)<\/td><\/tr><tr><td><strong>Treatment Duration<\/strong><\/td><td>Up to two years, followed by treatment discontinuation until disease progression<\/td><\/tr><tr><td><strong>Key Finding<\/strong><\/td><td>Statistically significant and clinically meaningful PFS improvement with Jaypirca combination<\/td><\/tr><tr><td><strong>Subgroup Analysis<\/strong><\/td><td>Consistent benefits observed regardless of prior covalent BTK inhibitor therapy status<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory submissions, and commercial expectations for Jaypirca. Actual results may differ due to risks including regulatory review outcomes, competitive developments, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase III BRUIN&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63076,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,17,199,911,33],"class_list":["post-63075","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-results","tag-eli-lilly","tag-nyse-lly","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly&#039;s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL\/SLL Trial \u2013 Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase III BRUIN CLL-322 clinical trial, demonstrating that Jaypirca (pirtobrutinib) in combination with venetoclax and rituximab significantly improved progression-free survival (PFS) compared to venetoclax plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63075\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly&#039;s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL\/SLL Trial \u2013 Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase III BRUIN CLL-322 clinical trial, demonstrating that Jaypirca (pirtobrutinib) in combination with venetoclax and rituximab significantly improved progression-free survival (PFS) compared to venetoclax plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63075\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-14T06:10:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T06:10:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1402.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63075#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63075\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly&#8217;s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL\\\/SLL Trial \u2013 Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History\",\"datePublished\":\"2026-04-14T06:10:41+00:00\",\"dateModified\":\"2026-04-14T06:10:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63075\"},\"wordCount\":378,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63075#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1402.webp\",\"keywords\":[\"Cancer\",\"Clinical trial results\",\"Eli Lilly\",\"NYSE: LLY\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63075#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63075\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63075\",\"name\":\"Eli Lilly's Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL\\\/SLL Trial \u2013 Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63075#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63075#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1402.webp\",\"datePublished\":\"2026-04-14T06:10:41+00:00\",\"dateModified\":\"2026-04-14T06:10:42+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase III BRUIN CLL-322 clinical trial, demonstrating that Jaypirca (pirtobrutinib) in combination with venetoclax and rituximab significantly improved progression-free survival (PFS) compared to venetoclax plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\\\/SLL).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63075#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63075\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63075#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1402.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1402.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly's Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL\\\/SLL Trial \u2013 Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63075#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly&#8217;s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL\\\/SLL Trial \u2013 Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly's Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL\/SLL Trial \u2013 Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase III BRUIN CLL-322 clinical trial, demonstrating that Jaypirca (pirtobrutinib) in combination with venetoclax and rituximab significantly improved progression-free survival (PFS) compared to venetoclax plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63075","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly's Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL\/SLL Trial \u2013 Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History","og_description":"Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase III BRUIN CLL-322 clinical trial, demonstrating that Jaypirca (pirtobrutinib) in combination with venetoclax and rituximab significantly improved progression-free survival (PFS) compared to venetoclax plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL).","og_url":"https:\/\/flcube.com\/?p=63075","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-14T06:10:41+00:00","article_modified_time":"2026-04-14T06:10:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1402.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63075#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63075"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly&#8217;s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL\/SLL Trial \u2013 Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History","datePublished":"2026-04-14T06:10:41+00:00","dateModified":"2026-04-14T06:10:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63075"},"wordCount":378,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63075#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1402.webp","keywords":["Cancer","Clinical trial results","Eli Lilly","NYSE: LLY","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63075#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63075","url":"https:\/\/flcube.com\/?p=63075","name":"Eli Lilly's Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL\/SLL Trial \u2013 Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63075#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63075#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1402.webp","datePublished":"2026-04-14T06:10:41+00:00","dateModified":"2026-04-14T06:10:42+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase III BRUIN CLL-322 clinical trial, demonstrating that Jaypirca (pirtobrutinib) in combination with venetoclax and rituximab significantly improved progression-free survival (PFS) compared to venetoclax plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63075#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63075"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63075#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1402.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1402.webp","width":1080,"height":608,"caption":"Eli Lilly's Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL\/SLL Trial \u2013 Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63075#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly&#8217;s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL\/SLL Trial \u2013 Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1402.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63075"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63075\/revisions"}],"predecessor-version":[{"id":63077,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63075\/revisions\/63077"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63076"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}